Key points
- MoU signed to integrate AI and digital tools in drug development
- Partnership to link Merck SaaS with Siemens Xcelerator platform
- Initial pilots include AI rollout on Siemens’ Dotmatics platform
- Firms eye future co-development of data tools and marketplaces
ISLAMABAD: Merck, a German science and technology company, and Siemens, the industrial technology group, have signed a new Memorandum of Understanding (MoU) to expand their strategic partnership and accelerate digital transformation in life sciences.
The agreement, announced in Darmstadt, Germany, on Tuesday, will connect Merck’s software-as-a-service portfolio with Siemens’ Xcelerator digital platform to deliver end-to-end workflows from discovery to manufacturing. It is the first collaboration since Siemens completed its. July 2025, acquisition of Dotmatics, a joint statement said.
Initial pilot projects would embed Merck’s AI-driven applications into Siemens’ Dotmatics Scientific Intelligence Platform, creating a single environment where scientists can access digital tools, data insights, and product ordering. Both companies stated future projects would include co-developing data management tools, intuitive interfaces, and digital marketplaces for life science technologies.
Jean-Charles Wirth, CEO Life Science at Merck, said the tie-up would allow scientists to “move faster from an idea in the lab to a therapy for patients.” Siemens board member Cedrik Neike said AI and digitalisation were key to reversing rising drug development costs, stressing that a digital backbone would help “connect every step of drug development.”
Merck employs more than 62,000 people and generated €21.2 billion in sales in 2024, while Siemens reported €75.9 billion in revenue and €9.0 billion net income in the same year, with around 312,000 employees worldwide.
